ZNF692 and neoplasm: However, upon exposure to immune checkpoint blockade (ICB) agents, a portion of ZNF692-positive tumor cells (referred to as tumor program 1 cluster (TP1) cells) in advanced ccRCC patients responded to ICB therapy.